Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH).
Icon’s quarterly earnings hit by biotech and pharma pullback
Cost and research cuts across biotech and pharma are affecting some of the contracting companies that rely on the industry. The latest victim is Icon
October 25, 2024